BOVNF (BioInvent International AB) Institutional Ownership: 15.10% (As of Jul. 13, 2026)


BOVNF BioInvent International AB BOVNF
39 GF Score
Price $3.29
GF Value $7.07
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Institutional Ownership?

BioInvent International AB BOVNF 39 Institutional Ownership is 15.10% as of Jul. 13, 2026. GuruFocus rates BOVNF with a GF Score™ of 39/100 and a GF Value™ of $7.07. The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BioInvent International AB's institutional ownership is 15.10%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BioInvent International AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BioInvent International AB's Float Percentage Of Total Shares Outstanding is 0.00%.

BioInvent International AB Institutional Ownership Historical Data

* Premium members only.

The historical data trend for BioInvent International AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioInvent International AB Institutional Ownership Chart

BioInvent International AB Historical Data

The historical data trend for BioInvent International AB can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 14.64 14.52 14.41 14.26 14.19 14.23 14.20 14.24 14.31 14.31
BOVNF
39GF Score
BioInvent International AB BOVNF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioInvent International AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 15.10% mean?
BioInvent International AB (BOVNF) has a Institutional Ownership of 15.10% as of Jul. 13, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on BioInvent International AB and its competitors.
Is BioInvent International AB's Institutional Ownership too high?
BioInvent International AB's current Institutional Ownership is 15.10%. Overall, BioInvent International AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Institutional Ownership compare to VRTX and REGN?
BioInvent International AB's Institutional Ownership of 15.10% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on BioInvent International AB and its competitors. BioInvent International AB's current Institutional Ownership is 15.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (BOVNF) has a current Institutional Ownership of 15.10%. The stock's GF Value™ is $7.07, compared to a current price of $3.29 — trading 53.5% below its estimated fair value. The current Institutional Ownership is 15.10%. BioInvent International AB's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For BioInvent International AB (BOVNF), the current Institutional Ownership is 15.10% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioInvent International AB (BOVNF) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of $3.29 is trading 53.5% below its estimated GF Value™ of $7.07.

Key valuation signals for BOVNF:

  • Institutional Ownership: 15.10%
  • GF Value™: $7.07 vs. price of $3.29 (53.5% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioInvent International AB Business Description

Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
39GF Score

Get the complete analysis for BOVNF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price
$7.07
GF Value